Verified July 2026 · Cited to primary sources

Thymosin Beta-4: Evidence Grade B. Real human trials, limited or historical.

Grade BResearch-onlySafety: amber

The honest verdict

Two different stories share one molecule. As an eye drop (RGN-259) it has legitimate positive human trials and grades a B. As the injectable TB-500 that the recovery crowd actually buys, human efficacy data is basically absent, and you are extrapolating from animal healing studies. It is not FDA-approved in any form. If you are drawn to it for tendon or muscle recovery, be clear-eyed that you are self-experimenting with an unapproved, WADA-banned peptide whose human evidence lives in ophthalmology, not sports medicine.

Thymosin Beta-4 at a glance

Class
Actin-sequestering regenerative peptide
Mechanism
The main job of thymosin beta-4 is to bind and sequester G-actin, the building-block protein of the cell skeleton. By managing the actin pool it drives cell migration, which is central to wound healing. It also promotes new blood vessel growth (angiogenesis), tamps down inflammatory signaling, and can reduce cell death after injury. TB-500 is a widely sold fragment marketed as a related actin-binding peptide. These mechanisms explain the interest in healing, cardiac repair, and the cornea.
Also known as
Tbeta4, RGN-259, Thymosin beta 4
Research applications
  • Neurotrophic keratopathy and severe dry eye (as the RGN-259 eye drop)
  • Skin and soft-tissue wound healing
  • Cardiac repair after heart attack (preclinical)
  • Corneal and epithelial regeneration
  • Muscle and tendon injury recovery (mostly anecdotal in the injectable form)
Forms
Ophthalmic solution (RGN-259, investigational eye drop), Subcutaneous or intramuscular injection (TB-500 research fragment)
Legal status
Research-only
WADA (anti-doping)
TB-500 / thymosin beta-4 is prohibited in sport by WADA. It falls under the S2 growth-factor category as an agent affecting tissue repair and angiogenesis. Athletes have been sanctioned for it.
Evidence grade
Grade BReal human trials, limited or historical

How we grade evidence

Every grade comes from a fixed A to F rubric: human-trial strength, not hype or affiliate status. Last verified July 6, 2026.

What is Thymosin Beta-4?

A 43-amino-acid tissue-repair peptide. It has real human eye-drop trials (RGN-259) but is not FDA-approved, and the injectable bodybuilding version (TB-500) has essentially no human data.

The main job of thymosin beta-4 is to bind and sequester G-actin, the building-block protein of the cell skeleton. By managing the actin pool it drives cell migration, which is central to wound healing. It also promotes new blood vessel growth (angiogenesis), tamps down inflammatory signaling, and can reduce cell death after injury. TB-500 is a widely sold fragment marketed as a related actin-binding peptide. These mechanisms explain the interest in healing, cardiac repair, and the cornea.

How strong is the evidence for Thymosin Beta-4?

Higher than pure preclinical because thymosin beta-4 has actually run positive human randomized trials, but only as an eye drop. A phase 2 RCT in severe dry eye hit significant endpoints (35% less ocular discomfort, 59% less corneal staining vs vehicle), and a phase 3 RCT in neurotrophic keratopathy showed strong healing (6/10 vs 1/8 healed, significant by day 43). A first-in-human phase 1 confirmed injectable recombinant Tbeta4 was well tolerated. That said: it is not FDA-approved (the phase 3 SEER-3 ocular program later missed its primary endpoint), cardiac and systemic-healing claims rest on animal models, and the injected TB-500 that people actually buy has almost no human efficacy data. So B for the molecule on its ophthalmic trials, with the honest caveat that the injectable use is far less supported.

Primary sources (3)

  1. Thymosin beta4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial (Cornea, 2015)
  2. 0.1% RGN-259 (thymosin beta4) for neurotrophic keratopathy: randomized, placebo-controlled, double-masked phase 3 trial (Int J Mol Sci, 2022)
  3. First-in-human phase 1 study of recombinant human thymosin beta4 in healthy volunteers (J Cell Mol Med, 2021)

What is Thymosin Beta-4 used for?

Thymosin Beta-4 is marketed for the goals below. See how it ranks against other peptides in each, by evidence, not hype.

Best peptides for Recovery & Healing →

What does Thymosin Beta-4 cost, and how do you access it legally?

Typical cost

$30 to $70 per vial (research-grade TB-500, typically 5mg to 10mg)

TB-500 research vials are cheap and widely sold, but purity and actual peptide identity are unverified. The RGN-259 eye drop is an investigational drug, not a consumer product, and is not available for purchase.

No legal supervised access route right now.

Thymosin Beta-4 has no compliant US route today. Vials sold "for research use only" are a gray-market fig-leaf, not a legal loophole, so we don't link them. If you pursue Thymosin Beta-4, do it with a licensed clinician, and re-check its legal status first.

Is Thymosin Beta-4safe? Side effects & risks

Limited human safety data, no major documented harms

The eye-drop trials and the phase 1 injectable study reported good tolerability with no serious adverse events, which is reassuring. But that data does not transfer to the doses and injection routes people use with TB-500 for muscle recovery. A recurring theoretical concern with a pro-angiogenic, pro-migration peptide is cancer: if it helps tissue grow, it could in principle help unwanted tissue grow too, and long-term human safety at systemic doses is unstudied. Injectable TB-500 is research-only with no purity oversight. Not something to inject casually.

Medical disclaimer: This page is independent editorial information, not medical advice, and Best Peptide For That is not a medical provider. We do not provide dosing. Talk to a licensed clinician before starting, stopping, or changing any peptide or medication. Full medical disclaimer.

FAQ

Thymosin Beta-4 FAQ

Is TB-500 the same as thymosin beta-4?

Close but not identical. Thymosin beta-4 is the full 43-amino-acid natural peptide. TB-500 is marketed as a related actin-binding fragment. The human trials were done with full thymosin beta-4 (as RGN-259 eye drops or recombinant Tbeta4), not with the injectable TB-500 sold for recovery.

Is there human evidence it heals injuries?

The strongest human data is for the eye: significant results in dry eye and neurotrophic keratopathy trials. For muscle, tendon, and systemic injury recovery, the evidence is animal studies plus anecdote, not controlled human trials.

Is it FDA-approved?

No. It holds orphan drug designation for neurotrophic keratopathy but has no FDA marketing approval in any form, and the late-stage ocular program has stumbled on its primary endpoints. It is also banned in sport by WADA.

From our portfolio

Tracking Thymosin Beta-4?

Titrate is an iOS app for logging doses, schedules and progress over time, with a reconstitution calculator built in. It tracks, it does not prescribe.

Get Titrate for iOS →

Keep reading

Grade D

BPC-157

The most-hyped, least-human-proven "healing" peptide. Extensive rodent data, zero published human trials.

Grade D

TB-500

The other half of the "wolverine stack." Soft-tissue recovery claims, but only animal data for the fragment actually sold.

Grade D

KPV

An anti-inflammatory tripeptide studied for gut and skin inflammation. Promising in cells and animals, untested in humans.

How we grade the evidence →Are peptides safe? →FDA peptide status 2026 →

The monthly peptide evidence brief.

What the research and the FDA actually say, in one short email a month. Unsubscribe anytime.

No spam. We never sell your email. Editorial policy.